Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of PD-1 negative CD8 effector T-cells in advanced HCC with single-cell sequencing

ABSTRACT: Immune checkpoint inhibitors (CPI) have dramatically changed the treatment landscape of advanced HCC (aHCC), but factors associated with response/resistance to CPI remain to be elucidated. The main aim of this project was to identify features associated with response and/or resistance to checkpoint inhibitors in advanced HCC at the single-cell resolution. We subjected both pre-treatment tissue biopsies and serial peripheral blood mononuclear cell (PBMC) samples of aHCC patients (n=44) treated with systemic therapy to droplet-based single-cell transcriptome (scRNAseq) and T-cell receptor sequencing (scTCRseq) using Chromium Single Cell V(D)J Solution. Doing so, we obtained high quality transcriptomic data for tissue biopsies and PBMC samples.

PROVIDER: EGAS00001007547 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Multi-omics Identifies Tumor-Intrinsic SREBP1 Driving Immune Exclusion in Hepatocellular Carcinoma

Project description:Immune checkpoint inhibitors (ICI) have improved patient outcomes in hepatocellular carcinoma (HCC); however most patients do not experience durable benefit. The non-T cell-inflamed tumor microenvironment (TME), characterized by limited CD8+ T cell infiltration, reduced dendritic cell function, and low IFNγ-associated gene expression, is associated with lower likelihood of response to ICI. To nominate new therapeutic targets for overcoming ICI resistance in HCC, we conduced single cell RNAseq using 10X Genomics on 6 primary HCC tumors.

2025-06-24 | GSE292298 | GEO

Xenium Spatial Transcriptomics Reveals the Mechanism of TGFBRIIDN-Armored GPC3-CAR-T Cells in Hepatocellular Carcinoma Patients

Project description:The GPC3-specific TGFBRII dominant-negative (DN) armored CAR-T cell therapy demonstrated promising clinical efficacy in phase I trials for advanced hepatocellular carcinoma (HCC). To investigate the spatial mechanisms of tumor response and resistance, we performed Xenium in situ spatial transcriptomic analysis on 18 samples from 13 patients of longitudinally collected FFPE tumor biopsies, enabling single-cell resolution mapping of tumor-immune interactions throughout the treatment course.

2026-05-26 | GSE332850 | GEO

scRNAseq reveals mechanisms of Merkel cell carcinoma acquired immunotherapy resistance [1]

Project description:Serial blood draws from a single patient and serial tumor biopsies from the same patient with metastatic Merkel cell polyomavirus Merkel cell carcinoma, who was treated with cellular immunotherapy targeting MCPyV (autologous endogenous T cell therapy) followed by checkpoint inhibitors (anti-PD1 and anti-CTLA4). The patient had a 22 month clinical response followed by late/acquired resistance. We performed scRNAseq using the 10x genomics 3' Chromium expression assay to determine potential mechanisms contributing to immunotherapy response and late resistance

2018-09-01 | GSE117988 | GEO

Pharmacoproteomics identifies kinase pathways that drive the epithelial-mesenchymal transition and drug resistance in hepatocellular carcinoma

Project description:Hepatocellular carcinoma (HCC) is a complex and deadly disease lacking druggable genetic mutations. The limited efficacy of systemic treatments for advanced HCC implies that novel predictive biomarkers and drug targets are urgently needed. Most HCC drugs target protein kinases and their kinase-dependent signaling networks to drive HCC progression. To identify HCC signaling networks that determine responses to kinase inhibitors (KIs), we apply a pharmacoproteomics approach integrating kinome activity in 17 HCC cell lines with their responses to 299 KIs, resulting in a comprehensive dataset of pathway-based drug response signatures. By profiling patient HCC samples, we identify signatures of clinical HCC drug responses in individual tumors. Our analyses reveal kinase networks promoting the epithelial-mesenchymal transition (EMT) and drug resistance, including a FZD2-AXL-NUAK1/2 signaling module, whose inhibition reverses the EMT and sensitizes HCC cells to drugs. Our approach identifies cancer drug targets and molecular signatures of drug response for personalized oncology.

2018-12-15 | MSV000083236 | MassIVE

T cell populations correlate with response and resistance to anti-PD-1 plus lenvatinib combination therapy in hepatocellular carcinoma

Project description:The combination of immune checkpoint blockade and tyrosine kinase inhibitors has shown promising clinical benefits, but the underlying mechanisms driving response and resistance are poorly understood. Here, we performed single-cell RNA- and TCR-sequencing, together with a HBV-peptide-barcoded single-cell RNA-sequencing approach, on paired tumor and blood samples to track the dynamic changes of T cells in HBV+ hepatocellular carcinoma (HCC) patients before or after anti-PD-1 plus lenvatinib combination therapy.

2024-12-17 | GSE235863 | GEO

Combined Immunotherapy and Particle Therapy for Advanced HCC with Macrovascular Invasion: Phase Ib DEPARTURE Trial

Project description:Hepatocellular carcinoma (HCC) with macrovascular invasion carries a poor prognosis, necessitating novel therapeutic strategies. This phase Ib trial evaluated the safety and preliminary efficacy of combining carbon-ion radiotherapy with immune checkpoint inhibitors in patients with advanced HCC. RNA-seq was conducted to investigate changes in the tumor microenvironment, aiming to identify molecular signatures predictive of response or resistance to the combination therapy. The reduction group showed enrichment of pathways related to inflammation, complement activation, which are often associated with immune activity. In contrast, the progression group exhibited enrichment of pathways linked to mesenchymal characteristics and angiogenesis, processes that may correlate with reduced therapy efficacy.

2026-04-01 | GSE287319 | GEO

Locoregional delivery of autologous PD-1 knockout T cell in patients with failed first-line therapy in advanced hepatocellular carcinoma

Project description:The study aims to evaluate the efficacy and safety of a novel cell-based therapy for advanced hepatocellular carcinoma (HCC). Current guidelines for advanced HCC recommend systemic therapies, such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs); however, their combined efficacy as first-line treatments remains suboptimal. This study reports findings from a first-in-human phase I clinical trial involving 3 patients with advanced HCC who had previously demonstrated poor responses to first-line therapies. The treatment involved local intratumoral injection of CRISPR-edited, PD1-deleted T lymphocytes, engineered to enhance antitumor immunity (ClinicalTrials.gov NCT04417764). Key outcomes include a treatment response rate of 90% among assessable patients, with a median survival after enrolment of 17.2 months and an overall median survival after HCC diagnosis of 46.9 months. As of December 31, 2023, the three-year survival rate was 20%, and one patient exhibited an exceptional survival duration of 43.6 months. Secondary outcomes revealed that patients receiving the engineered T-cell therapy reported a significantly improved quality of life compared to the observation group. The tumor immune microenvironment was analyzed pre- and post-therapy using single-cell RNA sequencing, which demonstrated that tumor-infiltrating lymphocytes (TILs) developed an effector-like phenotype following therapy. In conclusion, this study provides strong evidence supporting the viability of CRISPR-edited, PD1-deleted T lymphocytes as a therapeutic option for advanced HCC, addressing an urgent need for more effective treatment strategies in this patient population.

2026-01-18 | GSE287386 | GEO

Tsur2019 - Response of patients with melanoma to immune checkpoint blockade

Project description:This is a simple mathematical population model for pembrolizumab-treated advanced melanoma patients, used to predict the response of melanoma patients to immune checkpoint inhibitors.

2024-09-02 | BIOMD0000000838 | BioModels

The novel protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment

Project description:Metabolic reprogramming fuels cancer cell metastasis and remodels the immunosuppressive tumor microenvironment (TME). We report here that a circRNA, circPETH, packaged by extracellular vesicles (EVs) from tumor-associated macrophages (TAMs) to hepatocellular carcinoma (HCC) cells, facilitates glycolysis and metastasis of recipient HCC cells. Mechanistically, circPETH-147aa, encoded by circPETH in a m6A-driven manner, promotes PKM2-catalyzed ALDOA-S36 phosphorylation via MEG pocket. Furthermore, circPETH-147aa impairs anti-HCC immunity by elevating HuR-dependent SLC43A2 mRNA stability and driving methionine and leucine deficiency in cytotoxic CD8+ T cells. Importantly, by virtual and experimental screening, we found that the novel small-molecule Norathyriol was an effective inhibitor that targets the MEG pocket on circPETH-147aa surface. Norathyriol reverses circPETH-147aa-facilitated acquisition of metabolic and metastatic phenotypes by HCC cells, increases anti-PD1 efficacy and boosts cytotoxic CD8+ T-cell function. Our findings determine Norathyriol as a promising anti-HCC agent that contributes to the attenuation of advanced HCC resistance to immune checkpoint blocker (ICB) therapies.

2024-12-09 | MTBLS11254 | MetaboLights

Melanoma Sequential Immune Checkpoint Blockade Treatment Sequencing Study

Project description:<p>Blockade of T cell coinhibitory molecules such as CTLA-4 and PD-1, can activate T cell antitumor response. Although these immune checkpoint blockades (CTLA-4 blockade and PD-1 blockade) have shown durable response, response rate is modest. Therefore, there is a need to find stable biomarkers predictive of response to immune checkpoint blockades and to understand underlying resistance mechanisms. We collected longitudinal tumor biopsies from a cohort of metastatic melanoma patients treated with sequential immune checkpoint blockades and performed whole exome sequencing of this cohort. The comprehensive genomic characterization of tumors enabled identification of higher copy number loss burden as a resistance mechanism and clonal T cell repertoire as a predictive biomarker.</p>

| phs001425 | dbGaP

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data